middle.news
Recce advances RECCE 327 trial as key Indonesian review nears
12:04pm on Friday 30th of October, 2026 AEDT
•
Biotechnology and Pharmaceuticals
Read Story
Recce advances RECCE 327 trial as key Indonesian review nears
12:04pm on Friday 30th of October, 2026 AEDT
Key Points
208-patient active-controlled Phase 3 design approved for RECCE 327 topical gel
Indonesian Phase 3 data submitted for potential mid-November DMC review
Vietnamese patent extends protection for RECCE 327 and RECCE 529 to 2041
A$3.6 million R&D rebate received, with a further A$7.5 million expected
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE